167 related articles for article (PubMed ID: 1354963)
61. Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.
Schott B; Londos-Gagliardi D; Ries C; Huet S; Robert J
J Cancer Res Clin Oncol; 1993; 119(9):527-32. PubMed ID: 8100823
[TBL] [Abstract][Full Text] [Related]
62. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
[TBL] [Abstract][Full Text] [Related]
63. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
64. Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase pi gene expression.
Ramachandran C; Yuan ZK; Huang XL; Krishan A
Biochem Pharmacol; 1993 Feb; 45(3):743-51. PubMed ID: 8095141
[TBL] [Abstract][Full Text] [Related]
65. Saturable function of P-glycoprotein as a drug-efflux pump in multidrug-resistant tumour cells.
Miyamoto KI; Koga-Takeda K; Koga K; Ohshima T; Nomura M
J Pharm Pharmacol; 1996 May; 48(5):522-5. PubMed ID: 8799879
[TBL] [Abstract][Full Text] [Related]
66. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
67. Differential growth inhibition of isoquinolinesulfonamides H-8 and H-7 towards multidrug-resistant P388 murine leukaemia cells.
Ido M; Nagao Y; Higashigawa M; Shibata T; Taniguchi K; Hamazaki M; Sakurai M
Br J Cancer; 1991 Dec; 64(6):1103-7. PubMed ID: 1684908
[TBL] [Abstract][Full Text] [Related]
68. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
69. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
70. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
71. Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
Millot JM; Rasoanaivo TD; Morjani H; Manfait M
Br J Cancer; 1989 Nov; 60(5):678-84. PubMed ID: 2803945
[TBL] [Abstract][Full Text] [Related]
72. Multidrug resistance bypass in cells exposed to doxorubicin-loaded nanospheres. Absence of endocytosis.
Henry-Toulmé N; Grouselle M; Ramaseilles C
Biochem Pharmacol; 1995 Oct; 50(8):1135-9. PubMed ID: 7488226
[TBL] [Abstract][Full Text] [Related]
73. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells.
Tahara K; Kato Y; Yamamoto H; Kreuter J; Kawashima Y
J Microencapsul; 2011; 28(1):29-36. PubMed ID: 21171814
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo.
Miyamoto K; Inoko K; Wakusawa S; Kajita S; Hasegawa T; Takagi K; Koyama M
Cancer Res; 1993 Apr; 53(7):1555-9. PubMed ID: 8095855
[TBL] [Abstract][Full Text] [Related]
75. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
76. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
77. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells.
Granzotto M; Rapozzi V; Decorti G; Giraldi T
J Pineal Res; 2001 Oct; 31(3):206-13. PubMed ID: 11589754
[TBL] [Abstract][Full Text] [Related]
78. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.
Trendowski M; Mitchell JM; Corsette CM; Acquafondata C; Fondy TP
Invest New Drugs; 2015 Apr; 33(2):290-9. PubMed ID: 25563824
[TBL] [Abstract][Full Text] [Related]
79. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
Gupta S; Patel K; Singh H; Gollapudi S
Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
[TBL] [Abstract][Full Text] [Related]
80. Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells.
Damle BD; Sridhar R; Desai PB
Int J Cancer; 1994 Jan; 56(1):113-8. PubMed ID: 8262666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
